Reversal of docetaxel resistance with bevacizumab and thalidomide

Yang Min Ning; William Figg; William Dahut

doi:10.3816/CGC.2009.n.020

Reversal of docetaxel resistance with bevacizumab and thalidomide

Yang Min Ning, William Figg, William Dahut^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Taxane resistance is a common clinical problem in the treatment of many metastatic malignancies. Observational clues or evidence of overcoming such resistance is important for developing treatments that can extend taxane activity. We report a case of the reversal of docetaxel resistance with the addition of antiangiogenic agents bevacizumab and thalidomide to docetaxel and prednisone in a patient with metastatic castration-resistant prostate cancer after PSAWG progression on docetaxel and prednisone. The patient then responded for an additional 7 months. The addition of bevacizumab and thalidomide after progression on docetaxel/prednisone might reverse docetaxel resistance. These or other antiangiogenic agents for overcoming clinical taxane resistance are candidates for further study.

Original language	English
Pages (from-to)	E37-E38
Journal	Clinical Genitourinary Cancer
Volume	7
Issue number	2
DOIs	https://doi.org/10.3816/CGC.2009.n.020
State	Published - 2009
Externally published	Yes

Keywords

Antiangiogenesis
Castration-resistant prostate cancer
Reversal of taxane resistance

Access to Document

10.3816/CGC.2009.n.020

Cite this

@article{dd3656d050eb4a5f9765c943accdb672,

title = "Reversal of docetaxel resistance with bevacizumab and thalidomide",

abstract = "Taxane resistance is a common clinical problem in the treatment of many metastatic malignancies. Observational clues or evidence of overcoming such resistance is important for developing treatments that can extend taxane activity. We report a case of the reversal of docetaxel resistance with the addition of antiangiogenic agents bevacizumab and thalidomide to docetaxel and prednisone in a patient with metastatic castration-resistant prostate cancer after PSAWG progression on docetaxel and prednisone. The patient then responded for an additional 7 months. The addition of bevacizumab and thalidomide after progression on docetaxel/prednisone might reverse docetaxel resistance. These or other antiangiogenic agents for overcoming clinical taxane resistance are candidates for further study.",

keywords = "Antiangiogenesis, Castration-resistant prostate cancer, Reversal of taxane resistance",

author = "Ning, {Yang Min} and William Figg and William Dahut",

note = "Funding Information: These observations suggest that docetaxel resistance might be overcome by antiangiogenic agents such as bevacizumab and thalidomide. Recent reports have recently shown that a small percentage of patients with docetaxel-resistant mCRPC might respond to docetaxel rechallenge as second-line therapy4-6; however, it is not clear if the responses in those patients were due to partially resumed sensitivity after a prolonged docetaxel-free interval before the rechallenge or due to other agents (ie, carboplatin), which may have also exerted their antitumor activity against the disease. Unlike some of these reports, our case demonstrated the reversal of docetaxel resistance only 4 weeks after PSAWG progression. The single-agent activity of bevaci-zumab and thalidomide are both very modest in this disease and thus a response of this magnitude and duration would have been unlikely This project has been supported by the Intramural Research Program of the National Cancer Institute, Center for Cancer Research, National Institutes of Health. The observations discussed herein do not represent the views of the federal agencies nor does mention of the combined antiangiogenic therapy imply approval by these agencies.",

year = "2009",

doi = "10.3816/CGC.2009.n.020",

language = "English",

volume = "7",

pages = "E37--E38",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Reversal of docetaxel resistance with bevacizumab and thalidomide

AU - Ning, Yang Min

AU - Figg, William

AU - Dahut, William

N1 - Funding Information: These observations suggest that docetaxel resistance might be overcome by antiangiogenic agents such as bevacizumab and thalidomide. Recent reports have recently shown that a small percentage of patients with docetaxel-resistant mCRPC might respond to docetaxel rechallenge as second-line therapy4-6; however, it is not clear if the responses in those patients were due to partially resumed sensitivity after a prolonged docetaxel-free interval before the rechallenge or due to other agents (ie, carboplatin), which may have also exerted their antitumor activity against the disease. Unlike some of these reports, our case demonstrated the reversal of docetaxel resistance only 4 weeks after PSAWG progression. The single-agent activity of bevaci-zumab and thalidomide are both very modest in this disease and thus a response of this magnitude and duration would have been unlikely This project has been supported by the Intramural Research Program of the National Cancer Institute, Center for Cancer Research, National Institutes of Health. The observations discussed herein do not represent the views of the federal agencies nor does mention of the combined antiangiogenic therapy imply approval by these agencies.

PY - 2009

Y1 - 2009

N2 - Taxane resistance is a common clinical problem in the treatment of many metastatic malignancies. Observational clues or evidence of overcoming such resistance is important for developing treatments that can extend taxane activity. We report a case of the reversal of docetaxel resistance with the addition of antiangiogenic agents bevacizumab and thalidomide to docetaxel and prednisone in a patient with metastatic castration-resistant prostate cancer after PSAWG progression on docetaxel and prednisone. The patient then responded for an additional 7 months. The addition of bevacizumab and thalidomide after progression on docetaxel/prednisone might reverse docetaxel resistance. These or other antiangiogenic agents for overcoming clinical taxane resistance are candidates for further study.

AB - Taxane resistance is a common clinical problem in the treatment of many metastatic malignancies. Observational clues or evidence of overcoming such resistance is important for developing treatments that can extend taxane activity. We report a case of the reversal of docetaxel resistance with the addition of antiangiogenic agents bevacizumab and thalidomide to docetaxel and prednisone in a patient with metastatic castration-resistant prostate cancer after PSAWG progression on docetaxel and prednisone. The patient then responded for an additional 7 months. The addition of bevacizumab and thalidomide after progression on docetaxel/prednisone might reverse docetaxel resistance. These or other antiangiogenic agents for overcoming clinical taxane resistance are candidates for further study.

KW - Antiangiogenesis

KW - Castration-resistant prostate cancer

KW - Reversal of taxane resistance

UR - http://www.scopus.com/inward/record.url?scp=70449345814&partnerID=8YFLogxK

U2 - 10.3816/CGC.2009.n.020

DO - 10.3816/CGC.2009.n.020

M3 - Article

C2 - 19692321

AN - SCOPUS:70449345814

SN - 1558-7673

VL - 7

SP - E37-E38

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 2

ER -

Reversal of docetaxel resistance with bevacizumab and thalidomide

Abstract

Keywords

Access to Document

Fingerprint

Cite this